**Question:** Not to be used in the treatment of thrombotic thrombocytopenic purpura (TTP)-

A. Platelet aggregation inhibitors
B. Antithrombin III augmentation
C. Vascular endothelial growth factor (VEGF) inhibitors
D. Immunosuppressive agents

**Core Concept:**
TTP, an acquired life-threatening disorder, is characterized by microangiopathic hemolytic anemia, thrombocytopenia, and renal dysfunction. It is caused by deficiency or inactivation of the enzyme ADAMTS13 (a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13), which cleaves von Willebrand factor (VWF) multimers, preventing the formation of large, pathogenic VWF-platelet aggregates.

**Why the Correct Answer is Right:**
TTP is a unique condition where platelet aggregation plays a crucial role in the pathogenesis. The correct answer, D - Immunosuppressive agents, is wrong because these medications target the immune system and inflammation, which may not address the underlying issue of ADAMTS13 deficiency or inactivation.

**Why Each Wrong Option is Incorrect:**
A. Platelet aggregation inhibitors (Option A): Although TTP is associated with functional platelet deficiency, targeting platelet aggregation would not correct the primary defect and may even exacerbate the disease by further compromising the clearance of VWF-platelet aggregates.

B. Antithrombin III augmentation (Option B): Antithrombin III is a natural anticoagulant that inhibits thrombin generation. It does not address the primary issue of ADAMTS13 deficiency or inactivation.

C. Vascular endothelial growth factor (VEGF) inhibitors (Option C): VEGF is a pro-angiogenic factor involved in neovascularization. TTP is a platelet disorder, not an angiogenic condition, so targeting VEGF would not be relevant or effective.

**Clinical Pearl:**
The correct diagnosis and treatment of TTP depend on identifying the deficiency or inactivation of ADAMTS13. Treatment involves plasma exchange therapy, which replaces deficient ADAMTS13, and corticosteroids or other immunosuppressive agents as adjunct therapy to prevent autoimmune attack on the remaining functional ADAMTS13.